Top of this page
Skip navigation, go straight to the content

Passionate about enabling families with severe diseases to enjoy normal, everyday lives

Building the next generation biopharma leader
Discover how we are connecting patients, people and science in new ways to make breakthroughs in severe diseases

Read moreLorem

The power to make a difference

A global biopharma focused on severe diseases with operations in more than 40 countries and global revenue of € 3.1 billion in 2009.

  • We combine biology and chemistry to make major breakthroughs. By integrating our expertise in large, antibody-based molecules and small, chemically-derived molecules, we can offer families with severe diseases and their specialist physicians the advantages of both large and small molecules to produce extraordinary breakthroughs.
  • We partner with the leaders in the pharmaceutical industry. The complexities of severe diseases are beyond the expertise and resources of a single organisation. That is why we have teamed up with partners - we play to our strengths and tap into the organisations with greater or complementary strengths.

Many companies claim to be patient-driven, but for UCB it is a living reality. In fact, we do not think of people with severe diseases as "patients" but as individuals with lives beyond their disease.

Quick access


Find an office



image description